bluuebunny/crossref_metadata_2025_split huggingface dataset:
Paternal Exposure to Methotrexate and Pregnancy Outcomes
Authors: BEGHIN DELPHINE , COURNOT MARIE-PIERRE , VAUZELLE CATHERINE , ELEFANT ELISABETH 
Published: January 2011

Objective.To assess the risk of major malformation in the case of paternal exposure to methotrexate (MTX) at the time of conception.Methods.Using prospective data of our Teratology Information Service, we analyzed outcomes of paternal MTX exposure at the time of conception or up to 3 months before conception.Results.We report on the outcomes of 42 pregnancies involving 40 men treated with MTX at the time of conception. Twenty-three men were treated for an inflammatory disease (54.8%), 9 for psoriasis (21.4%), and 8 for a malignant disease (19.0%). Weekly dosages varied between 7.5 mg and 30 mg. The pregnancies resulted in 36 live births, 3 spontaneous abortions, and 3 voluntary abortions. No congenital malformation was observed at birth.Conclusion.Based on our results and case reports in literature, paternal MTX exposure at the time of conception does not seem to raise any major concern for offspring.
Clinical Features of Lupus Cystitis Complicated with Hydroureteronephrosis in a Chinese Population: Table 1.
Authors: ZHANG GUOJUAN , LI HANG , HUANG WEN , LI XUEMEI , LI XUEWANG 
Published: January 2011

Objective.Lupus cystitis is a relatively rare complication of systemic lupus erythematosus (SLE). The clinical characterization of it remains obscure. We sought to provide insight for timely recognition and diagnosis of lupus cystitis, and for efficacious management of this disease entity.Methods.The clinical files of 18 patients with lupus cystitis treated at Peking Union Medical College Hospital were reviewed. Clinical manifestations, laboratory investigations, therapeutic measurements, and clinical outcomes were analyzed.Results.There were both male and female patients with a wide range of ages. The interval from onset of SLE to hydroureteronephrosis varied from 0 to 5 years. The most common clinical presentations were gastrointestinal (GI) symptoms, while urinary symptoms were less common and relatively mild. Lupus nephritis often presented concomitantly with lupus cystitis but was relatively less active pathologically. Laboratory findings showed a high rate of positive anti-SSA. Therapy of prednisone plus cyclophosphamide was effective for lupus cystitis. Delayed diagnosis and treatment may lead to irreversible obstructive uropathy and permanent loss of renal function.Conclusion.Lupus cystitis may not be so rare as has been thought. The diagnosis of lupus cystitis should be considered when patients with SLE present with GI symptoms, and therapy should begin as early as possible.
Association ofIRF5Polymorphisms with Susceptibility to Macrophage Activation Syndrome in Patients with Juvenile Idiopathic Arthritis
Authors: YANAGIMACHI MASAKATSU , NARUTO TAKUYA , MIYAMAE TAKAKO , HARA TAKUMA , KIKUCHI MASAKO , HARA RYOKI , IMAGAWA TOMOYUKI , MORI MASAAKI , SATO HIDENORI , GOTO HIROAKI , YOKOTA SHUMPEI 
Published: January 2011

Objective.Systemic-onset juvenile idiopathic arthritis (systemic JIA) and macrophage activation syndrome (MAS), the most devastating complication of systemic JIA, are characterized by abnormal levels of proinflammatory cytokines. Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, and acts as a master transcription factor in the activation of genes encoding proinflammatory cytokines. Polymorphisms in theIRF5gene have been associated with susceptibility to autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Our aim was to assess associations ofIRF5gene polymorphisms with susceptibility to systemic JIA and MAS.Methods.ThreeIRF5single-nucleotide polymorphisms (rs729302, rs2004640, and rs2280714) were genotyped using TaqMan assays in 81 patients with systemic JIA (33 with MAS, 48 without) and 190 controls.Results.There were no associations of theIRF5gene polymorphisms or haplotypes under study with susceptibility to systemic JIA. There was a significant association of the rs2004640 T allele with MAS susceptibility (OR 4.11; 95% CI 1.84, 9.16; p = 0.001). TheIRF5haplotype (rs729302 A, rs2004640 T, and rs2280714 T), which was reported as conferring an increased risk of SLE, was significantly associated with MAS susceptibility in patients with systemic JIA (OR 4.61; 95% CI 1.73, 12.3; p < 0.001).Conclusion.IRF5gene polymorphism is a genetic factor influencing susceptibility to MAS in patients with systemic JIA, and IRF5 contributes to the pathogenesis of MAS in these patients.
Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis
Authors: LAUNOIS ROBERT , AVOUAC BERNARD , BERENBAUM FRANCIS , BLIN OLIVIER , BRU ISABELLE , FAUTREL BRUNO , JOUBERT JEAN-MICHEL , SIBILIA JEAN , COMBE BERNARD 
Published: January 2011

Objective.To compare the clinical efficacy of certolizumab pegol (CZP) with that of other anticytokine agents indicated for the treatment of rheumatoid arthritis (RA) with identical therapeutic indication (anti-tumor necrosis factor-α, anti-interleukin 1 or 6), with the objective of determining the noninferiority of CZP.Methods.A systematic review was performed to identify randomized controlled trials that assessed the efficacy of anticytokine agents in combination with conventional disease-modifying antirheumatic drugs (DMARD) after 6 months of treatment, using the American College of Rheumatology (ACR) response criteria, in patients with RA who have shown inadequate response to DMARD including methotrexate. Indirect treatment comparisons were carried out by a multiple-treatment Bayesian random-effects metaanalysis. Data were analyzed using the Markov chain Monte Carlo simulation. Noninferiority of CZP was assessed in comparison with a predefined equivalence margin of 5%.Results.Nineteen placebo-controlled studies were identified: 14 evaluated the efficacy of 5 anti-TNF-α agents (infliximab, etanercept, adalimumab, golimumab, CZP) and 5 evaluated efficacy of 2 anti-interleukin agents (anakinra, tocilizumab). Every treatment showed significant efficacy versus placebo in individual studies. The multiple-treatment metaanalysis showed a highest OR for CZP on ACR20 response. Metaanalysis indicates that the efficacy of CZP according to ACR20 response is superior to that of infliximab, adalimumab, and anakinra, and equivalent or superior to that of etanercept, golimumab, and tocilizumab. According to ACR50 response, the efficacy of CZP is equivalent or superior to that of all other anticytokines.Conclusion.Results of this original multiple-treatment Bayesian metaanalysis indicate that certolizumab pegol is at least as efficacious as the preexisting antirheumatic anticytokine biotherapies.
Malignancies in Juvenile Idiopathic Arthritis: A Preliminary Report: Table 1.
Authors: BERNATSKY SASHA , ROSENBERG ALAN M. , OEN KIEM G. , DUFFY CIARAN M. , RAMSEY-GOLDMAN ROSALIND , LABRECQUE JEREMY , ST. PIERRE YVAN , CLARKE ANN E. 
Published: January 2011

Objective.To present preliminary data on incidence of malignancy in juvenile idiopathic arthritis (JIA), compared to general population rates.Methods.We examined cancer occurrence within JIA registries at 3 Canadian pediatric rheumatology centers. The subjects in the clinic registries were linked to regional tumor registries to determine the occurrence of invasive cancers over the observation period (spanning 1974–2006). The total number of cancers expected was determined by multiplying the person-years in the cohort by age, sex, and calendar year-specific cancer rates. The standardized incidence ratio (SIR, ratio of cancers observed to expected) was generated, with 95% confidence intervals.Results.The study sample consisted of 1834 patients. The female proportion was 67.6%; average age at entry to cohort was 8.6 years (SD 5.1). The majority were Caucasian. Subjects contributed 22,341 patient-years (average 12.2, SD 7.8). Within this observation period, one invasive cancer occurred, compared to 7.9 expected (SIR 0.12, 95% CI 0.0, 0.70). This was a hematological cancer (Hodgkin’s lymphoma), representing a SIR for hematological malignancies of 0.76 (95% CI 0.02, 4.21).Conclusion.Only one invasive cancer was identified in this large sample of individuals with JIA, observed for an average of 12.2 years each. These data suggest that, at least in the initial years following diagnosis of JIA, the risk of invasive cancers overall is not markedly increased. The results do not rule out the possibility of a baseline increased risk of hematological malignancies.
Functional Polymorphisms of the Coagulation Factor II Gene (F2) and Susceptibility to Systemic Lupus Erythematosus
Authors: DEMIRCI F. YESIM K. , DRESSEN AMY S. , KAMMERER CANDACE M. , BARMADA M. MICHAEL , KAO AMY H. , RAMSEY-GOLDMAN ROSALIND , MANZI SUSAN , KAMBOH M. ILYAS 
Published: January 2011

Objective.TwoF2functional polymorphisms, rs1799963 (G20210A) and rs3136516 (A19911G), are known to be associated with elevated levels/activity of prothrombin (encoded byF2) and risk of thrombosis. Since patients with systemic lupus erythematosus (SLE) have high risk of thrombosis and accelerated atherosclerosis and also high prevalence of anti-prothrombin antibodies, we hypothesized that these twoF2polymorphisms could affect risk of SLE.Methods.We investigated these polymorphisms in 627 women with SLE (84% Caucasian Americans, 16% African Americans) and 657 female controls (78% Caucasian Americans, 22% African Americans).Results.While the rs1799963 A allele was almost absent in African Americans, it was present at ∼2% frequency in Caucasian Americans and showed no significant association with SLE. The rs3136516 G allele frequency was significantly higher in Caucasian SLE cases than in controls (48.4% vs 43.7%, respectively) with a covariate-adjusted odds ratio (OR) of 1.22 (95% CI 1.03–1.46, p = 0.023). The association was replicated in African Americans (rs3136516 G allele frequency 91.2% in cases vs 82.2% in controls) with an adjusted OR of 1.96 (95% CI 1.08–3.58, p = 0.022). Stratification of Caucasian SLE patients based on the presence or absence of cardiac and vascular events (CVE) revealed stronger association with the CVE-positive SLE subgroup than the CVE-negative SLE subgroup (OR 1.42 vs 1.20). Prothrombin activity measurements in a subset of SLE cases demonstrated higher activity in the carriers of the rs3136516 G allele.Conclusion.Our results suggest a potential role for prothrombin and the crosstalk between hemostatic and immune/inflammatory systems in SLE and SLE-associated cardiovascular events, which warrants further investigation in independent samples.
Incidence and Mortality of Treated Primary Sjögren’s Syndrome in Taiwan: A Population-based Study
Authors: WENG MENG-YU , HUANG YU-TUNG , LIU MING-FEI , LU TSUNG-HSUEH 
Published: January 2011

Objective.To estimate the incidence and mortality of treated primary Sjögren’s syndrome (pSS) by sex and age group in Taiwan.Methods.We used claims data of the Bureau of National Health Insurance (NHI) of Taiwan from 2005 to 2007 for analysis. According to the NHI, pSS is classified as one of the financially catastrophic illnesses and patients with pSS could be exempted from copayment of all medical costs. To obtain a catastrophic illness certificate (CIC) for pSS, patients are required to meet the criteria of the American-European Consensus Group for pSS, and are reviewed by a committee. Patients approved for receipt of a CIC for pSS for the first time were defined as incident cases of treated pSS.Results.A total of 3352 incident cases occurred between 2005 and 2007. The estimated mean annual incidence was 6.0 per 100,000 inhabitants (95% CI 5.8–6.2) for both sexes, 11.0 (95% CI 10.6–11.4) for women and 1.1 (95% CI 1.0–1.2) for men, with a female/male ratio of 9.9 (95% CI 8.8–11.1). Incidence increased with age, peaking at age 55–64 years in women and 65–74 years in men. The mortality rate was 33.4 per 1000 case person-years for men and 11.4 for women, with a male/female rate ratio of 2.9 (95% CI 1.7–5.3).Conclusion.The incidence of treated pSS in women is 10 times that in men. Nevertheless, pSS mortality in men is 3 times that in women.
Clinical Spectrum, Treatment, and Outcome of Patients with Type II Mixed Cryoglobulinemia without Evidence of Hepatitis C Infection
Authors: FOESSEL LAURE , BESANCENOT JEAN-FRANÇOIS , BLAISON GILLES , MAGY-BERTRAND NADINE , JAUSSAUD ROLAND , ETIENNE YVES , MAURIER FRANÇOIS , AUDIA SYLVAIN , MARTIN THIERRY 
Published: January 2011

Objective.The clinical spectrum, etiologies, and best therapeutic approaches of type II mixed cryoglobulinemia (MC) not associated with hepatitis C virus (HCV) infection have been poorly described to date. We studied the clinical presentation and outcome of patients with type II MC with no evidence of HCV.Methods.This was a multicenter retrospective study on the clinical presentation and outcome of patients with type II MC without evidence of HCV infection. Only patients with symptomatic MC were included.Results.Thirty-three patients were included (median followup 67.2 mo). Extensive investigations for associated diseases were performed at presentation. MC was related to an autoimmune disease in 14 patients, to a lymphoid malignancy in 4 patients, and to an infectious disease in 2 patients, while MC was classified as essential (primary) in 13. Essential MC tended to be more severe than secondary disease with, in particular, more frequent renal and peripheral nerve involvement. Most patients were treated with steroid with or without immunosuppressive agents, mainly cyclophosphamide. These treatments were unable to induce sustained remission. One patient was successfully treated with lenalidomide. Seven patients with nonmalignant MC were treated with rituximab; 2 had a sustained complete remission, 3 improved greatly but relapsed within 5 months, and 2 experienced a disease flare.Conclusion.An important proportion of non HCV-related type II MC remains essential. Efforts should be made to find other etiologies than HCV, because treatments with steroid and immunosuppressants are not satisfactory, especially in severe forms. In these situations anti-CD20 therapy may present the best option but should be used with caution. New agents such as lenalidomide remain to be evaluated.
Valproic Acid Suppresses Interleukin-1ß-induced Microsomal Prostaglandin E2Synthase-1 Expression in Chondrocytes Through Upregulation of NAB1
Authors: ZAYED NADIA , EL MANSOURI FATIMA EZZAHRA , CHABANE NADIR , KAPOOR MOHIT , MARTEL-PELLETIER JOHANNE , BENDERDOUR MOHAMED , PELLETIER JEAN-PIERRE , DUVAL NICOLAS , FAHMI HASSAN 
Published: January 2011

Objective.Microsomal prostaglandin E2synthase-1 (mPGES-1) catalyzes the terminal step in the biosynthesis of PGE2. Early growth response factor-1 (Egr-1) is a key transcription factor in the regulation of mPGES-1, and its activity is negatively regulated by the corepressor NGF1-A-binding protein-1 (NAB1). We examined the effects of valproic acid (VA), a histone deacetylase inhibitor, on interleukin 1ß (IL-1ß)-induced mPGES-1 expression in human chondrocytes, and evaluated the roles of Egr-1 and NAB1 in these effects.Methods.Chondrocytes were stimulated with IL-1 in the absence or presence of VA, and the level of mPGES-1 protein and mRNA expression were evaluated using Western blotting and real-time reverse-transcription polymerase chain reaction (PCR), respectively. mPGES-1 promoter activity was analyzed in transient transfection experiments. Egr-1 and NAB1 recruitment to the mPGES-1 promoter was evaluated using chromatin immunoprecipitation assays. Small interfering RNA (siRNA) approaches were used to silence NAB1 expression.Results.VA dose-dependently suppressed IL-1-induced mPGES-1 protein and mRNA expression as well as its promoter activation. Treatment with VA did not alter IL-1-induced Egr-1 expression, or its recruitment to the mPGES-1 promoter, but prevented its transcriptional activity. The suppressive effect of VA requiresde novoprotein synthesis. VA induced the expression of NAB1, and its recruitment to the mPGES-1 promoter, suggesting that NAB1 may mediate the suppressive effect of VA. Indeed, NAB1 silencing with siRNA blocked VA-mediated suppression of IL-1-induced mPGES-1 expression.Conclusion.VA inhibited IL-1-induced mPGES-1 expression in chondrocytes. The suppressive effect of VA was not due to reduced expression or recruitment of Egr-1 to the mPGES-1 promoter and involved upregulation of NAB1.
Surgery for Shoulder Osteoarthritis: A Cochrane Systematic Review
Authors: SINGH JASVINDER A. , SPERLING JOHN , BUCHBINDER RACHELLE , McMAKEN KELLY 
Published: January 2011

Objective.To determine the benefits and harm of surgery for shoulder osteoarthritis (OA).Methods.We performed a Cochrane Systematic Review of clinical trials of adults with shoulder OA, comparing surgical techniques [total shoulder arthroplasty (TSA), hemiarthroplasty, implant types, and fixation] to placebo, sham surgery, nonsurgical modalities, and no treatment. We also reviewed trials that compared various surgical techniques, reporting patient-reported outcomes (pain, function, quality of life, etc.) or revision rates. We calculated the risk ratio for categorical outcomes and mean differences for continuous outcomes with 95% CI.Results.There were no controlled trials of surgery versus placebo or nonsurgical interventions. Seven studies with 238 patients were included. Two studies compared TSA to hemiarthroplasty (n = 88). Significantly worse scores on the 0–100 American Shoulder and Elbow Surgeons scale (mean difference, −10.05 at 24–34 mo; 95% CI −18.97 to −1.13; p = 0.03) and a nonsignificant trend toward higher revision rate in hemiarthroplasty compared to TSA (relative risk 6.18; 95% CI 0.77 to 49.52; p = 0.09) were noted. With 1 study providing data (n = 41), no differences were noted between groups for pain scores (mean difference 7.8; 95% CI −5.33 to 20.93), quality of life on Medical Outcomes Study Short-Form 36 physical component summary (mean difference 0.80; 95% CI −6.63 to −8.23), and adverse events (relative risk 1.2; 95% CI 0.4 to 3.8).Conclusion.TSA was associated with better shoulder function, with no other demonstrable clinical benefits compared to hemiarthroplasty. More studies are needed to compare clinical outcomes between them and comparing shoulder surgery to sham, placebo, and other nonsurgical treatment options.
Cartilage Destruction Is Partly Induced by the Internal Proteolytic Enzymes and Apoptotic Phenomenon of Chondrocytes in Relapsing Polychondritis
Authors: OUCHI NAOHISA , UZUKI MIWA , KAMATAKI AKIHISA , MIURA YASUHIRO , SAWAI TAKASHI 
Published: January 2011

Objective.We analyzed 9 cases by immunohistochemical studies in order to elucidate the mechanisms of cartilage destruction in relapsing polychondritis (RP), which often involves the external auricle and respiratory tract through immunological disorder.Methods.Cartilage tissues were obtained during surgical operations. Cell species in the granulation tissues, especially near the cartilage, were identified by cell-surface markers [CD3, CD4, CD8, CD20, CD45 (LCA), and CD68]. The proteolytic enzymes expressed in the cells in the perichondral granulation and in chondrocytes themselves were analyzed by immunohistochemical studies using anti-matrix metalloproteinase (MMP) -1, -3, -8, -9, and -13, and cathepsin D, K, L, and elastase antibodies. Apoptosis and nitric oxide (NO), an apoptosis-related factor, were also examined using ApopTag and antinitrotyrosine antibody, respectively.Results.Among cell species that infiltrated in perichondral granulation, LCA, CD68 (monocytes/macrophages), and CD4 cells were dominant in number; MMP-8, MMP-9, and elastase were expressed only in the perichondral granulation; whereas MMP-3 and cathepsin K and L were detected in both chondrocytes and granulations. Out of 9 cases examined, 6 revealed apoptotic cells in excess of 50% of chondrocytes. There was a strong correlation between the number of apoptotic cells and the number of MMP-3-positive (r = 0.83) and cathepsin K-positive cells (r = 0.92). Abundant NO-expressing cells were observed in the chondrocytes in degenerated cartilage, similar to apoptosis.Conclusion.Cartilage destruction in polychondritis is induced not only by perichondral inflammation, but also by intrinsic factors expressed in chondrocytes themselves, including certain kinds of proteolytic enzymes and apoptosis.
The True Gift : Thoughts on L'Année sociologique Edition of 1923-4
Authors: Guyer I. 
Published: January 2011

Le « vrai » don : réflexions à propos de L’Année sociologique, année 1923-1924 L’ouverture constitutive du don suscite inspiration et critique. Cet article reprend cette question en resituant l’ Essai sur le don dans sa matrice, l’édition 1923-1924 de L’Année sociologique , où il fut d’abord publié. Mauss signe d’autres textes dans ce numéro, y compris de nombreuses recensions et un in memoriam aux morts depuis 1912. Cet article analyse l’édition de L’Année dans son intégralité en faisant le parallèle avec la pratique funéraire juive du chesed shel emet (le don véritable) pour revenir sur la « bonté » dans l’ Essai .
Highly Efficient Suzuki–Miyaura Coupling of Aryl Tosylates and Mesylates Catalyzed by Stable, Cost‐Effective [1,3‐Bis(diphenylphosphino)propane]nickel(II) Chloride [Ni(dppp)Cl2] with only 1 mol% Loading
Authors: Gao Han , Li You , Zhou Yi‐Guo , Han Fu‐She , Lin Ying‐Jie 
Published: January 2011

AbstractWe present a highly active, inexpensive, universally applicable, and markedly stable [1,3‐bis(diphenylphosphino)propane]nickel(II) chloride [Ni(dppp)Cl2] catalyst that is capable of effecting the Suzuki–Miyaura cross‐coupling of the inherently less reactive but readily available aryl tosylates and mesylates with only 1 mol% loading and in the absence of extra supporting ligand. Under the optimized reaction conditions, cross‐coupling of a wide range of activated, non‐activated, and deactivated, as well as sterically hindered and heteroaromatic substrates (36 examples) could proceed efficiently to afford the coupled products in 53–99% yields. Consequently, the results presented in this work provide a significant advance in Suzuki–Miyaura cross‐coupling in terms of generality, practicality, and cost which are key concerns in recent research regarding transition metal‐catalyzed cross‐couplings.